thederma

Thederma is a global innovative drug research and development company focused on the development of therapies targeting AhR for autoimmune inflammatory diseases. Thederma concentrates deeply on immune-mediated related disease areas and is dedicated to the research and development of innovative drugs in fields with significant clinical needs, such as the central nervous system, ENT, respiratory, and dermatological diseases. As a pioneering leader in the field of international immunology small-molecule new drugs, Dr. Genghui Chen, CEO of Thederma, is a co-inventor of the world's first topical new drug (First-in-class) targeting AhR. He has led the entire process from discovery, clinical trials, industrialization, to registration and market launch of this drug. The drug has been approved for marketing in both China and the United States, making it the first original topical new drug developed in China to be launched domestically ahead of overseas markets. Thederma aims to lead innovation through science, seek breakthroughs through technology, and strive to provide more effective solutions to human health issues, aspiring to become a leader in the field of global immune-mediated chronic inflammatory diseases.